Rakovina secures exclusivity on kt-5000 target profile

Preview text: Rakovina secures exclusivity on kt-5000 target profile Rakovina secures exclusivity on…

Sunday, Oct 18, 2026 at 4:14 PM EasternMailchimp

Rakovina TherapeuticsRakovina secures exclusivity on kt-5000 target profile

Fit to screenFull size

Using this email in an article? Credit: Rakovina Therapeutics email via They Sent It, with a link to this page. Full-size image

Use this example

Subject: Rakovina secures exclusivity on kt-5000 target profile
Preview text: Rakovina secures exclusivity on kt-5000 target profile Rakovina secures exclusivity on…
From: ir@rakovinatherapeutics.com
Brand: Rakovina Therapeutics
ESP: Mailchimp
Sent: Sun Oct 18, 2026, 4:14 PM ET
Resent: First sent Thu Oct 15, 2026, 10:30 AM ET
Size: 72 KB
Images: 7
Links: 12, 2 of them buttons
Subject length: 54 characters

Against Rakovina Therapeutics's usual

Sent in its busiest hour, 4 PM, which holds 33% of its emails. The subject is 54 characters; its average is 72.

Email headers

What the brand's servers put on this email. Our receiving servers, the address we subscribed with and unsubscribe links are left out.

Other sending headers (names only): X-Campaign, X-campaignid, X-Report-Abuse, X-MC-User, X-Accounttype

	Nov 4, 2026 10:45 AM	Live tomorrow: the kt-5000AI story with Kim Oishi, Dr. Mads Daugaard and Handol Kim
	Oct 30, 2026 11:32 AM	AI narrows the focus for our brain-targeted cancer drug
	Oct 22, 2026 4:17 PM	kt-5000AI update: what we’ve shown, and what’s next
	Oct 18, 2026 4:14 PM	Rakovina secures exclusivity on kt-5000 target profile (this email) · Resent
	Oct 15, 2026 10:30 AM	Rakovina secures exclusivity on kt-5000 target profile
	Oct 1, 2026 4:18 PM	Rakovina partners with Celvion: what it means for our ATR program
	Sep 17, 2026 4:45 AM	Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member